Janus Henderson Investors US’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Janus Henderson Investors US’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-3,200	Closed	-$527K	–	1241
2016 Q3	$527K	Hold	3,200	–	–	﹤0.01%	1108
2016 Q2	$457K	Hold	3,200	–	–	﹤0.01%	1103
2016 Q1	$411K	Sell	3,200 -100	-3%	-$11.8K	﹤0.01%	1072
2015 Q4	$493K	Buy	+3,300	New	+$559K	﹤0.01%	1095
2014 Q4	–	Sell	-2,300	Closed	-$544K	–	1138
2014 Q3	$544K	Buy	+2,300	New	+$586K	﹤0.01%	1013

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Janus Henderson Investors US's ICPT Position: Q4 2016 in Review

Janus Henderson Investors US sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2016, closing a stake of 3,200 shares — an estimated $527K sold.

Janus Henderson Investors US first reported a position in ICPT in Q3 2014 and held it in 5 quarters. The position peaked at $544K in Q3 2014. 159 funds tracked by Wall St. Rank hold ICPT as of Q4 2016.

Janus Henderson Investors US reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
Janus Henderson Investors US sold 3,200 Intercept Pharmaceuticals, Inc. shares in Q4 2016, an estimated $527K.
Janus Henderson Investors US first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2014 and held it in 5 quarters.
Janus Henderson Investors US's Intercept Pharmaceuticals, Inc. position peaked at $544K in Q3 2014.
159 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2016.

Based on Janus Henderson Investors US's 13F filing for Q4 2016, filed 14 Feb 2017.